Post-hoc evaluation of the CLAP trial data demonstrated that mutational changes affecting PIK3CA, PTEN, ERBB3, and components of the PI3K/AKT signaling cascade, combined with tumor mutational burden, could represent innovative prognostic indicators in individuals receiving anti-PD-1-based combination treatments for cervical carcinoma (63). The gene discussed is ERBB3; the disease is neoplasm.